ORPHA:313920
Epstein-Barr virus-associated gastric carcinoma
Also known as: EBV-associated gastric carcinoma · EBVaGC
Publications
1,070
Trials
1
Interventional, condition-specific
Researchers
1,078
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare form of gastric carcinoma characterized by a latent EBV infection in gastric carcinoma cells, diffuse-type histology, a proximal location (in the body and cardia of the stomach) and a relatively favorable prognosis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017784
- UMLS:C4274414
- NCIT:C162304
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,070 matched papers (803 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
1 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,070
1,070 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,070 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
803 in the last 10 years · low confidence
Phrase hits: 1,070 · MeSH hits: 0
Who's working on it?
1,078
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Luo B22 papers · 2026
Department of Medical Microbiology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China. Electronic address: qdluobing@163.com.
Papers in Europe PMC - 02Zhang Y18 papers · 2026
Department of Clinical Laboratory, Zibo Central Hospital, 54 Gongqingtuan Road, ZiBo, 255036, China; Department of Medical Microbiology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China.
Papers in Europe PMC - 03Liu W15 papers · 2026
Department of Medical Microbiology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China.
Papers in Europe PMC - 04Chen JN11 papers · 2026
1Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, No.600 Tianhe Road, Guangzhou 510630, PR China.
Papers in Europe PMC - 05Wang Y11 papers · 2026
Pediatric Surgery Department, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, Shaanxi 710000, P.R. China.
Papers in Europe PMC - 06Liu Y10 papers · 2026
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Genetics, Peking University Cancer Hospital and Institute, Haidian, Beijing, China.
Papers in Europe PMC - 07Shao CK10 papers · 2026
1Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, No.600 Tianhe Road, Guangzhou 510630, PR China.
Papers in Europe PMC - 08Sun L10 papers · 2025
Department of Pathology of the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, China.
Papers in Europe PMC - 09Du Y9 papers · 2026
Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Papers in Europe PMC - 10Fukayama M9 papers · 2023
Department of Pathology, The University of Tokyo Hospital, Tokyo, Japan. mfukayama-tky@umin.org.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; 1 currently recruiting in our sample. 115 trials are registered for gastric carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).
low confidence · 76.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05970627·NOT YET RECRUITING·Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Conditions: Adenocarcinoma of the Stomach · Adenocarcinoma of Esophagogastric Junction · Epstein-Barr Virus-Associated Gastric Carcinoma·Matched via name phrase
Broader category: gastric carcinoma
115
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05270824·NOT YET RECRUITING·Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
Conditions: Advanced Gastric Carcinoma · CD8+ Tumor Infiltrating Lymphocytes · Neoadjuvant Immunotherapy·Matched via name phrase
- NCT06944496·NOT YET RECRUITING·A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions: Gastric Carcinoma·Matched via name phrase
- NCT05705492·RECRUITING·Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
Conditions: Advanced Malignant Solid Neoplasm · Advanced Biliary Tract Carcinoma · Advanced Esophageal Carcinoma · Metastatic Esophageal Carcinoma·Matched via name phrase
- NCT06882746·RECRUITING·A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Conditions: Colorectal Carcinoma · Gastric Carcinoma · Pancreatic Ductal Adenocarcinoma·Matched via name phrase
- NCT05323929·RECRUITING·The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
Conditions: Early Gastric Cancer · Endoscopic Submucosal Dissection·Matched via name phrase
- NCT06730373·RECRUITING·First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Conditions: HER2-positive Gastric Cancer · Metastatic Gastric Cancer · Unresectable Gastric Carcinoma·Matched via name phrase
- NCT05593458·RECRUITING·Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
Conditions: Locally Advanced Gastric Carcinoma·Matched via name phrase
- NCT06792435·RECRUITING·XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Conditions: Pancreatic Adenocarcinoma Metastatic · Lung Cancer (NSCLC) · Ovarian Cancer · Colorectal Cancer Metastatic·Matched via name phrase
- NCT06645808·RECRUITING·PET-imaging of Two Vartumabs in Patients With Solid Tumors
Conditions: Solid Tumor · Colon Carcinoma · Rectal Carcinoma · Osteosarcoma·Matched via name phrase
- NCT04891016·RECRUITING·Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
Conditions: Chemotherapy · Immune Checkpoint Inhibitor · Locally Advanced Gastric Carcinoma·Matched via name phrase
- NCT07315750·RECRUITING·A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Conditions: Gastric Carcinoma·Matched via name phrase
- NCT05226169·RECRUITING·Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)
Conditions: Advanced Gastric Carcinoma·Matched via name phrase
- NCT06364410·RECRUITING·Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Conditions: Clinical Stage III Gastric Cancer AJCC v8 · Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage IV Gastric Cancer AJCC v8 · Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8·Matched via name phrase
- NCT06408220·RECRUITING·Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
Conditions: Gastric Carcinoma·Matched via name phrase
- NCT06028737·RECRUITING·Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Conditions: Gastric Cancer · Stomach Cancer · GastroEsophageal Cancer · Gastric Adenocarcinoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Epstein-Barr virus-associated gastric carcinoma" OR "EBV-associated gastric carcinoma" OR "EBVaGC"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Epstein-Barr virus-associated gastric carcinoma" OR "EBV-associated gastric carcinoma" OR "EBVaGC"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"gastric carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1070) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T13:01:15.296Z
